Printer Friendly

Browse Amyloidosis topic

Drug therapy subtopic

Articles

1-23 out of 23 article(s)
Title Author Type Date Words
US Food and Drug Administration Acceptance of New Drug Application for Investigational Vutrisiran for the Treatment of the Polyneuropathy of Hereditary ATTR Amyloidosis. Jun 24, 2021 850
Janssen Receives Two Positive CHMP Opinions Recommending Expanded Use of Darzalex Subcutaneous Formulation for New Indications in Europe. May 21, 2021 400
US FDA approves Janssen Biotech's DARZALEX FASPRO. Jan 18, 2021 151
US FDA approves Janssen Biotech's DARZALEX FASPRO. Jan 18, 2021 155
Janssen Receives FDA Approval of Darzalex Faspro as Treatment for Newly Diagnosed Patients with Light Chain Amyloidosis. Jan 18, 2021 285
Halozyme submits sBLA with US FDA for approval of DARZALEX FASPRO for treatment of patients with AL amyloidosis. Sep 11, 2020 241
Halozyme submits sBLA with US FDA for approval of DARZALEX FASPRO for treatment of patients with AL amyloidosis. Sep 11, 2020 237
Arbutus sells part of its Onpattro royalty interest to OMERS. Jul 2, 2019 320
US FDA Approves Vyndaqel and Vyndamax for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease. May 8, 2019 329
US FDA approves new treatments Vyndaqel and Vyndamax for heart disease caused by transthyretina[euro]'mediated amyloidosis. May 7, 2019 224
US FDA approves new treatments Vyndaqel and Vyndamax for heart disease caused by transthyretina[euro]'mediated amyloidosis. May 7, 2019 220
Recurrence of proteinuria after cessation of tocilizumab in patients with AA amyloidosis secondary to FMF. Yilmaz, Sedat; Tekgoz, Emre; Cinar, Muhammet Dec 1, 2018 2194
Alnylam Submits New Drug Application in Japan for Onpattro for Treatment of Hereditary ATTR Amyloidosis. Oct 1, 2018 1250
US Bioservices Selected by Alnylam Pharmaceuticals as a Specialty Pharmacy Partner for Onpattro. Aug 15, 2018 311
US FDA Approves First RNAi Therapeutic, Onpattro, for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults. Aug 14, 2018 489
The US FDA authorises Onpattro for the treatment of hereditary transthyretin-mediated amyloidosis under the new siRNAs drugs class. Drug overview Aug 13, 2018 312
The US FDA authorises Onpattro for the treatment of hereditary transthyretin-mediated amyloidosis under the new siRNAs drugs class. Drug overview Aug 13, 2018 308
Alnylam confirms FDA approves Onpattro to treat polyneuropathy caused by hATTR. Aug 10, 2018 227
FDA Grants Orphan Drug Designation to Alnylam's Investigational RNAi Therapeutic for the Treatment of Transthyretin-Mediated Amyloidosis. Jun 8, 2018 257
Primary systemic amyloidosis with skin and cardiac involvement: a case report. Horvat, Anja Trajber; Trcko, Katarina; Jurcic, Vesna; Marko, Pij Bogomir Case study Jan 1, 2018 1767
A[beta] Peptide Originated from Platelets Promises New Strategy in Anti-Alzheimer's Drug Development. Inyushin, Mikhail Y.; Sanabria, Priscila; Rojas, Legier; Kucheryavykh, Yuriy; Kucheryavykh, Lilia Report Jan 1, 2017 8443
Effectiveness of bortezomib in cardiac AL amyloidosis: a report of two cases. Nigrelli, Santi; Curciarello, Giuseppe; Ballo, Piercarlo; Michelassi, Stefano; Pizzarelli, Francesco Case study Jan 1, 2014 2952
Alnylam's amyloidosis drug reduces pathogenic TTR amyloid deposits in tissues. Apr 22, 2010 291

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |